NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…
RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…
Abaloparatide Appears Safe, Effective for Boosting BMD in Women 80 & Up
NEW YORK (Reuters Health)—Abaloparatide appears to be a safe and effective drug for increasing bone mineral density (BMD) in women 80 and older, new research shows. The study is a post hoc analysis of the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, which found patients who received abaloparatide subcutaneously for 18 months had increased…
Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
NEW YORK (Reuters Health)—After discontinuation of teriparatide, increases in bone mineral density (BMD) are greater with denosumab than with zoledronic acid, but whether that translates into a decreased fragility fracture risk remains unknown, researchers say. Teriparatide was the first anabolic treatment approved for osteoporosis in the U.S. It has been shown to increase BMD, and…
Dermatology Patients on Corticosteroids May Not Receive Osteoporosis Screenings; Plus FDA Approves ZTLido
A recent study found that dermatology patients taking long-term steroids are not always evaluated for steroid-induced osteoporosis…
Healthy Diet Linked to Lower Hip Fracture Risk in U.S. Women
(Reuters Health)—Eating an overall healthy diet is tied to a lower risk of hip fracture among women over age 50, a U.S. study suggests. Researchers analyzed decades’ worth of dietary and health data for more than 100,000 U.S. men and women. They found that women who scored highest on the American Healthy Eating Index-2010 (AHEI)…
Patients with Gout May Be More Likely to Develop Osteoporosis
NEW YORK (Reuters Health)—People with gout face a modestly increased risk, of about 20%, for developing osteoporosis, compared to people without gout, researchers in Taiwan suggest. In their population-based study to examine a possible association between gout and subsequent osteoporosis, Dr. Victor C. Kok of Asia University (Taiwan), Taichung, and colleagues retrospectively analyzed data from…
Baseline Bone Measures Predict Risk of Fragility Fracture in Postmenopausal
NEW YORK (Reuters Health)—Baseline measures of bone density, microarchitecture and strength predict the risk of fragility fractures in postmenopausal women, according to results from the Calgary CaMOS cohort. Changes in bone health were not associated with fracture risk, however, said Dr. Lauren A. Burt from the University of Calgary, Canada, who worked on the study….
Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk
NEW YORK (Reuters Health)—Use of epidural steroid injections (ESIs) “should be approached with prudence,” particularly in patients who are at risk for osteoporotic fractures, such as women of postmenopausal age, according to authors of a systematic review. Although the literature presents a mixed picture, ESIs in doses as low as 80 mg methylprednisolone equivalents seem…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 19
- Next Page »